What Epitopea’s MHRA-approved OVACT trial signals for off-the-shelf cancer vaccines
Find out how Epitopea’s CryptiVax-1001 trial could reshape RNA cancer vaccines and ovarian cancer treatment strategies.
No FDA advisory committee for MOLBREEVI: what Savara’s Day 74 Letter means for the August PDUFA review
Savara’s molgramostim BLA faces no FDA adcom. Analysis of what the August 2026 PDUFA date means for autoimmune PAP treatment access. Read more.